Welcome to the e-CCO Library!

P323: The Rate of and Risk of Dysplasia in Long Standing Ulcerative Colitis Patients Among Middle-Eastern Population
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Altuwaijiri, M.(1); Alharbi, O.(1); Alruthia, Y.(2); Aljebreen, A.(1); Almadi , M.(1); Almalki , Y.(1); Alrashed, A.W.(1); Alzahran, S.A.(1); Almuhaya, H.(1); Alhowaish, N.(1); Alshehri, K.F.(1); Alrushud , S.S.(1);Alanazi, W.S.(1);Azzam, N.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P324 Deep enteroscopy after balloon dilatation for differential diagnosis of small bowel stricture
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C.H. Lim, J. Kim

Created: Thursday, 30 January 2020, 10:12 AM
P324: Comparative short and long-term efficacy of infliximab and adalimumab in patients with ulcerative colitis refractory to corticosteroids: a retrospective study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Yoshimura*, M. Sako, M. Takazoe

Created: Friday, 22 February 2019, 9:49 AM
P324: Evaluation of ability to predict mucosal healing by quantitative fecal immunochemical test in ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim H.W.*1, Song G.A.2, Kang D.H.3, Choi C.W.3, Ryu D.G.3

Created: Wednesday, 20 February 2019, 10:36 AM
P324: Inter- and intra-observer variation of capsule endoscopic findings for the diagnosis of Crohn’s disease: A case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Esaki1*, E. Washio1, T. Morishita1, K. Sakamoto1, Y. Fuyuno1, A. Hirano1, J. Umeno1, T. Kitazono1, T. Matsumoto2, Y. Suzuki3

Created: Thursday, 21 February 2019, 9:14 AM
P324: Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update
Year: 2023
Source: ECCO’23 Copenhagen
Authors: DerksEduarda Wilhelmina, M.(1)*;van Lierop, L.(2);te Groen, M.(1);Kuijpers, C.(3);Nagtegaal, I.D.(4);Hoentjen, F.(2);
Created: Friday, 14 July 2023, 11:05 AM
P324: Predictors of corticosteroid-free remission after initiation of ustekinumab for ulcerative colitis: a real-world, multicenter cohort study in the United States
Year: 2021
Source: ECCO'21 Virtual
Authors: Dalal, R.(1);Esckilsen, S.(2);Barnes, E.(3);McClure, E.(1);Goodrick, H.(1);Allegretti, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P324: Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic review
Year: 2022
Source: ECCO'22
Authors: Gordon, M.(1);Sinopoulou, V.(1);Pana, M.(2);Moran, G.(2);
Created: Friday, 11 February 2022, 3:52 PM
P324: Tuberculosis infection under anti-TNF therapy – should we be looking for it?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Xavier*1,2,3, T. Cúrdia Gonçalves1,2,3, F. Dias de Castro1,2,3, J. Magalhães1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

Created: Friday, 22 February 2019, 9:41 AM
P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn’s disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, A. Sitibondo2, M. Cappello3, B. Scrivo3, A. Busacca3, A.C. Privitera4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, N. Belluardo7, E. Giangreco7, C. Bertolami8, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Created: Thursday, 30 January 2020, 10:12 AM
P325: Combination therapy with adalimumab and immunomodulators decreases incidence of intestinal resection in Crohn's disease patients previously treated with infliximab: a large, multicentre cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tanaka H.*1, Kamata N.2, Yamada A.3, Fujii T.4, Endo K.5, Yoshino T.6,7, Sugaya T.8, Kawaguchi T.9, Bamba S.10, Ishii M.11, Shinzaki S.12, Toya Y.13, Yanai Y.14, Yokoyama Y.15, Umeno J.16, Okada T.17, Kobayashi T.18, Nojima M.19, Hibi T.18 the ADJUST Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P325: Efficacy, safety, and long-term outcome of endoscopic dilation therapy for stricturing Crohn’s disease of the upper gastrointestinal tract: a combined analysis of 127 endoscopic balloon dilation procedures
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Bettenworth*1, M. M. Mücke1, A. Singh2, R. Lopez3, F. Rieder4, 5

Created: Friday, 22 February 2019, 9:49 AM
P325: Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Jairath*1, K. Lasch2, K. Chan3, S. Kanters4, J. Jansen4, C. Agboton5, H. Patel6

Created: Friday, 22 February 2019, 9:41 AM
P325: Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease
Year: 2022
Source: ECCO'22
Authors: Mtir, M.(1);Hassine, H.(1);Kahlaoui, F.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P325: Proton pump inhibitors are associated with a disabling course of Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Barrau, M.(1)*;Duru, G.(2);Nancey, S.(3);Phelip, J.M.(4);Cheifetz, A.(5);Papamichael, K.(5);Paul, S.(6);Xavier, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P325: Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Parakkal, D.(1);Johnson, A.(2);Fenster, M.(3);Ramos, G.(2);Zulqarnain, M.(4);Ullman, T.(3);Huang, L.(1);Gutierrez, A.(1);Bruss, A.(4);Ungaro, R.(5);Cohen, B.(6);Gaurav, S.(7);Anish, P.(8);Sasankan, P.(6);Costable, N.(5);Pekow, J.(9);Wang, W.(9);Rubin, D.(9);Ciorba, M.(1);Beniwal-Patel, P.(4);Loftus, E.(2);Yarur, A.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P325: Risk factors for lymph node involvement in patients undergoing ileal pouch-anal anastomosis for ulcerative colitis complicated by colorectal cancer in the biological years
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Rottoli1, F. Ghignone1*, M. Tanzanu1, L. Boschi1, F. Rizzello2, P. Gionchetti2, G. Poggioli1

Created: Thursday, 21 February 2019, 9:14 AM
P326 Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Mahmmod1, J.P.D. Schultheiss1, A.C.I.T.L. Tan2, M.W.M.D. Lutgens3, L.P.L. Gilissen4, N. Mahmmod5, A.E. van der Meulen - de Jong6, G. Dijkstra7, A.A. van Bodegraven8, B. Oldenburg1, H.H. Fidder1

Created: Thursday, 30 January 2020, 10:12 AM
P326: An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States
Year: 2021
Source: ECCO'21 Virtual
Authors: Ungaro, R.(1);Chou, B.(2);Mo, J.(3);Ursos, L.(4);Twardowski, R.(5);Candela, N.(6);Colombel, J.F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM